Acute Intermittent Porphyria Considerations for Oral Hydromorphone Absorption

Pathophysiology and Clinical Implications

Acute Intermittent Porphyria (AIP) is characterized by deficiency in porphobilinogen deaminase (PBGD), leading to accumulation of delta-aminolevulinic acid (ALA) and porphobilinogen (PBG) during acute attacks, which may theoretically impact drug absorption and clearance 1
Gastrointestinal manifestations are common during acute attacks, with abdominal pain being one of the most frequent symptoms, potentially affecting drug absorption 2

Patients with AIP have an increased risk of chronic kidney disease (CKD) and hypertension, with CKD reported in up to 29% of patients, which could affect drug clearance 3, 4
Porphyria-associated kidney disease (PAKD) occurs in up to 59% of patients with symptomatic AIP, potentially leading to accumulation of hydromorphone and its metabolites 4
Renal impairment could affect drug clearance, potentially leading to accumulation of hydromorphone and its metabolites 3, 4

During acute attacks, intravenous administration of medications may be preferable to oral routes due to potential GI involvement, and severe pain should be treated aggressively with appropriate analgesics 5
Regular monitoring of renal function is recommended (at least annually) in patients with AIP, with dose adjustments of medications necessary based on renal function 4
The American Gastroenterological Association recommends monitoring for hyponatremia and other electrolyte disturbances that may occur during attacks, as well as regular assessment of renal function for patients on chronic opioid therapy 3, 4, 5

The primary concern with medications in AIP is whether they may trigger or exacerbate attacks by inducing cytochrome P450 enzymes, with careful monitoring advised for hydromorphone 6
Alternative pain management strategies may be considered if concerns exist about medication absorption, with parenteral administration of hydromorphone considered if available 5, 6